Xcout Intel
Alopexx, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Alopexx, Inc. among biotechnology companies — ranked by similarity to what Alopexx, Inc. actually does, not by market-cap band.
Subscribe to see Alopexx, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Alopexx, Inc.
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Alopexx, Inc. at a glance
Alopexx, Inc. is a biotechnology company headquartered in United States. Its most recent funding round closed in September 2024. Xcout tracks 6 named people at Alopexx, Inc., including Daniel R. Vlock (Co-Founder, Chief Executive Officer and Chairman of the Board Designee).
Alopexx, Inc. leadership
- Daniel R. VlockCo-Founder, Chief Executive Officer and Chairman of the Board Designee
- Ann MacDougallIndependent Director Designee
- Gail H. CassellIndependent Director Designee
- Peter J. WerthDirector Designee
- Richard CohenIndependent Director Designee
- William W. ChinSenior Strategic Advisor, Director Designee
Alopexx, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | Undisclosed | 1 named | |
| Strategic | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Alopexx, Inc. competitors
Ranked by semantic similarity — how close each company is to Alopexx, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Similar biotechnology company
Qpex Biopharma, Inc. is a biopharmaceutical company located in San Diego, California, specializing in infectious disease solutions as part of the Shionogi Group.
Similar biotechnology company
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Similar biotechnology company
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Biotech
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Life Sciences
ArrePath is a biotechnology research company based in Princeton, New Jersey, focusing on AI-enabled oral small-molecule discovery. The company uses proprietary artificial intelligence and machine learning workflows proven in antibacterial discovery.
Similar biotechnology company
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Similar biotechnology company
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
Similar biotechnology company
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Similar biotechnology company
Adaptive Phage Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that is advancing the APT phage bank. The company focuses on developing phage-based therapeutics to address bacterial infections.
Life Sciences
Omniose is an early-stage biotechnology and life sciences company headquartered in Saint Louis, Missouri. The firm develops polysaccharide conjugate vaccines against serious bacterial threats using its proprietary technology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Alopexx, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Alopexx, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →